Latest news with #HDAC
Yahoo
3 days ago
- Business
- Yahoo
Epigenetics Market Anticipated to Achieve 11.8% CAGR
"Epigenetic Research Gains Momentum: Comprehensive Market Analysis Highlights Growing Clinical Relevance Across Various Diseases, Limited Clinical Applications in Oncology and Significant Market Potential Attracting New Entrants and Major Enterprises to the Epigenetics Products Market, Including Research Tools, Epigenetic Biomarker-Based IVDs and Targeted Therapeutics." Boston, June 03, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, the 'Global Epigenetics Markets' is projected to grow from $4.8 billion in 2024 to $8.5 billion by the end of 2029 at a compound annual growth rate (CAGR) of 11.8% from 2024 through 2029. The report offers quantitative and qualitative insights to help readers develop growth strategies, assess the market landscape and make informed business decisions. It covers various therapeutic classes, such as DNMT inhibitors, HDAC inhibitors, IDH inhibitors and EZH2 inhibitors. The report is segmented by study methods, clinical indications and drug classes. Additionally, it discusses industry growth drivers, restraints, trends, opportunities, competitive landscape and emerging technologies impacting the epigenetics market. The factors driving the market's growth include: Rising Cancer Rates: The increasing prevalence of cancer creates a demand for new treatments and diagnostic tools, driving epigenetic research to develop targeted therapies. Technological Advances: Innovations in tools like CRISPR and next-generation sequencing enhance our ability to study and manipulate epigenetic modifications, leading to better disease understanding and treatment. Increased Research Funding: More investment in biomedical research supports the development of new technologies and therapies, fostering innovation in epigenetics. Precision Medicine: The trend toward personalized treatments based on genetic profiles boosts the importance of epigenetics in developing effective, individualized therapies. Interest in Liquid Biopsy: Liquid biopsies offer a noninvasive way to detect and monitor diseases, and technological improvements are increasing their clinical adoption. Request a sample copy of the global market for epigenetics research tools and reagents, IVDs and therapeutics reports. Report Synopsis Report Metric Details Base year considered 2023 Forecast period considered 2024-2029 Base year market size $4.4 billion Market size forecast $8.5 billion Growth rate CAGR of 11.8% from 2024 to 2029 Segments covered Product type, study method, clinical indication, drug class and region Regions covered North America, Europe, Asia-Pacific and the Rest of the World (RoW) Market drivers The rising prevalence of cancer and unmet need in oncology. Advances in analytical technologies and tools. Increasing investment in biomedical research. The trend toward precision medicine. Growing interest in liquid biopsy. Interesting facts: Epigenetic drugs have been more clinically successful in hematological malignancies than solid tumors. Many companies are developing epigenetic biomarker-based blood tests for early cancer detection. Multicancer detection is a significant area of interest. Most epigenetic drugs in clinical trials and on the market are primarily focused on oncology areas, particularly hematological malignancies. Emerging startups: Helio Genomics: The company is developing a blood test for early cancer detection. Biomea Fusion Inc.: A clinical-stage biopharmaceutical company focused on the discovery and development of oral covalent small molecules to treat patients with metabolic disease and genetically defined cancers. The report addresses the following questions: What is the projected market size and growth rate of the epigenetics research tools, reagents, IVDs and therapeutics market? The global epigenetics market was estimated to be around $4.4 billion in 2023. It is projected to reach $8.5 billion in 2029, growing at a CAGR of 11.8% during the forecast period. What market segments are covered in the report? An in-depth analysis of the global epigenetics research tools, reagents, IVDs and therapeutics market, including historical data and market projection on sales by product type, study method, clinical indication, drug class and region. Which type segment will dominate the market by the end of 2029? The IVD type segment is anticipated to dominate the market by the end of 2029. Which market is growing fastest among all? The IVD segment is the fastest growing market. Leading companies in the market include: ACTIVE MOTIF INC. BIO-RAD LABORATORIES INC. BIO-TECHNE BRISTOL-MYERS SQUIBB CO. DAIICHI SANKYO CO., LTD. EXACT SCIENCES CORP. GUARDANT HEALTH HOLOGIC INC. LES LABORATOIRES SERVIER MERCK KGAA NUCLEIX PROMEGA CORP. QIAGEN REVVITY INC. (PERKINELMER) THERMO FISHER SCIENTIFIC INC. Related reports Include: Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets: This report examines the industry structure, competitive landscape and profiles of leading companies, including their products, financials and recent activities. It also evaluates business strategies in the competitive environment and segments the market by application, analysis purpose, biomarker type and platform. Regional analysis spans North America, Europe, Asia-Pacific and the Rest of the world. Global DNA Sequencing: Research, Applied and Clinical Markets: The report on DNA sequencing explores its current and future market potential, analyzing drivers, restraints and opportunities. The market is segmented by technology (NGS, TGS, pyrosequencing and Sanger sequencing), product and service, end user, application, disease category and region. Key regions covered are North America, Europe, Asia-Pacific and the Rest of the World. Navigate Uncertainty with ConfidenceIn times of rapid change and uncertainty, having the right insights can make all the difference. At BCC Research, we are here to support innovation and help you stay ahead. Our custom research reports provide a comprehensive, 360-degree view of your market landscape, giving you the clarity you need to make informed decisions. We believe that timely, expert market intelligence should be accessible to all. That is why, for a limited time, we're offering 30% off the price of any BCC Research report to help more organizations gain access to our latest data and insights. Purchase a copy of the report directly from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. CONTACT: BCC Research Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA Email: info@ Phone: +1 781-489-7301
Yahoo
22-05-2025
- Business
- Yahoo
Epigenetics Market Research Report 2024-2025 & 2029 - DNMT, IDH, HDAC, and EZH2, are Forecasted to Witness Significant Growth
Growth is driven by increasing epigenetic research influenced by clinical evidence linking epigenetics to various diseases. Epigenetic therapeutics, especially targeting DNMT, IDH, HDAC, and EZH2, are forecasted to see significant growth due to advancements in treatments for cancer. The comprehensive report analyzes market drivers, trends, and opportunities and includes data and insights to aid strategic decision-making. Profiles of leading companies, such as Bristol-Myers Squibb and Thermo Fisher Scientific, are featured. Epigenetics Market Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "Epigenetics Market" report has been added to global market for epigenetics research tools and reagents, IVDs and therapeutics is expected to grow from $4.8 billion in 2024 to $8.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.8% from 2024 through 2029. This report comprehensively analyzes the global market for epigenetics products, research tools and reagents, epigenetic biomarker-based in vitro diagnostics (IVDs) and epigenetics-targeted therapeutics. It offers both quantitative and qualitative insights to help readers formulate growth strategies, evaluate the market landscape, assess their competitive positions and make informed business decisions regarding epigenetics products and services. The scope of epigenetics-targeted therapeutics includes DNA methyltransferase (DNMT) inhibitors, histone deacetylase (HDAC) inhibitors, isocitrate dehydrogenase (IDH) inhibitors and zeste homolog 2 (EZH2) is the study of heritable changes in gene expression or activity that do not involve alterations to the DNA sequence itself. The global market for epigenetics research tools and reagents by study method was estimated at $1.8 billion in 2023. This market should reach $2.2 billion by the end of 2029, growing at a CAGR of 4.1% through the forecast period. The demand for new research tools remains constant as scientists strive to advance understanding and pursue groundbreaking mounting clinical evidence supporting the relevance of epigenetics in various diseases has fueled a surge in epigenetic research, thereby increasing the demand for high-quality reagents and research tools. The trend is expected to continue over the forecast period, yielding market therapeutics target and modulate epigenetic mechanisms to restore a more normal epigenomic configuration. The global market for epigenetic therapeutics market by drug class targeting DNMT, IDH, HDAC and EZH2 was estimated at $938.2 million in 2023. The market is expected to reach $1.9 billion by the end of 2029, growing at a CAGR of 11% over the forecast period. Emerging research demonstrates the potential of epigenetics-based therapeutics as a versatile and targeted treatment modality, offering a viable alternative to conventional chemotherapy. Scientific advances, the growing number of cancer patients and the unmet need in oncology are key growth factors of the epigenetic drugs report includes: Analyses of the trends in global markets for epigenetics technologies, with market revenue data from 2021 to 2023, estimates for 2024, and projected CAGRs through 2029 Estimates of the size and growth forecasts of the global epigenomics market, and a corresponding market share analysis by product type, study method, clinical indication, drug class and region Facts and figures pertaining to the market dynamics, technological advancements, regulatory landscape, and the impact of macroeconomic factors Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses Evaluation of recent patent activity and key granted and published patents in the industry Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook Profiles of leading companies, including Bristol-Myers Squibb Co., Les Laboratoires Servier, Exact Sciences Corp., Thermo Fisher Scientific Inc., and Qiagen Company Profiles Active Motif Inc. Bio-Rad Laboratories Inc. Bio-Techne Bristol-Myers Squibb Co. Daiichi Sankyo Co. Ltd. Exact Sciences Corp. Guardant Health Hologic Inc. Les Laboratoires Servier Merck KGaA Nucleix Promega Corp. Qiagen Revvity Inc. (Perkinelmer) Thermo Fisher Scientific Inc. Key Attributes: Report Attribute Details No. of Pages 115 Forecast Period 2024 - 2029 Estimated Market Value (USD) in 2024 $4.8 Billion Forecasted Market Value (USD) by 2029 $8.5 Billion Compound Annual Growth Rate 11.8% Regions Covered Global Key Topics Covered: Chapter 1 Executive Summary Market Outlook Scope of Report Market Summary Chapter 2 Market Overview Epigenetics Overview DNA Methylation Histone Modification RNA Modifications Epigenetic Modulators Chapter 3 Market Dynamics Market Dynamics Snapshot Market Drivers Rising Prevalence of Cancer and Unmet Need in Oncology Advances in Analytical Technologies and Tools Increasing Investment in Biomedical Research Trend Towards Precision Medicine Growing Interest in Liquid Biopsy Market Restraints From Bench to Bedside: The Translation Gap in Epigenetics Epigenetic Therapeutics: Limited Clinical Success Against Solid Tumors Stringent Regulatory Landscape Market Trends Combining Epigenetic Modifiers with Other Therapeutic Class Multi-omics Integration Long-Read Sequencing in Epigenetic Research Epigenetic Biomarkers-based Blood Test for Cancer Screening Chapter 4 Emerging Technologies and Developments Emerging Technologies Epigenome Editing Epitranscriptomics Bromodomain and Extra-Terminal Domain Inhibitors Menin Inhibitors Application Beyond Oncology Pipeline Analysis Overview Novel Epigenetic Therapeutics in Development in Phase 2 and Above Chapter 5 Market Segmentation Analysis Segmentation Breakdown Epigenetics Research Tools and Reagents Market, by Study Method Market Overview Market Size and Forecast DNA Methylation Histone Modification RNA Modification In Vitro Diagnostics (IVDs) Market, by Clinical Indication Market Overview Market Size and Forecast Epigenetic Therapeutics Market, by Drug Class Market Overview Market Size and Forecast Geographic Breakdown Epigenetics Research Tools and Reagents Market, by Region Market Size and Forecast North America Europe Asia-Pacific Rest of the World Chapter 6 Competitive Intelligence Research Tools and Reagents In Vitro Diagnostics Therapeutics Chapter 7 Sustainability in the Epigenetics Market: An ESG Perspective Introduction to ESG Key ESG Issues in Epigenetics Pharmaceuticals and Diagnostics Market Sustainability Practices in Pharmaceuticals Manufacturing Sustainable Packaging Key ESG Issues in Epigenetics Research Tools Market ESG Risk Ratings Score -- Understanding the Data Concluding Remarks Chapter 8 Appendix For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Epigenetics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
